AngioDynamics ANGO Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $37.81M-9.2% | $41.64M+7.4% | $38.76M-30.6% | $55.89M+24.9% | $44.76M-17.2% | ||
| $45.55M+2.5% | $44.43M+4.2% | $42.64M-0.6% | $42.89M-1.3% | $43.47M+0.7% | ||
| $58.58M-10.7% | $65.57M+5.3% | $62.26M+0.4% | $62.01M-1.7% | $63.11M-4.3% | ||
| $13.61M+40.2% | $9.71M-25.3% | $13M+72.5% | $7.54M-51.2% | $15.44M+26.6% | ||
| $155.55M-3.6% | $161.35M+3.0% | $156.66M-6.9% | $168.32M-2.3% | $172.27M-1.8% | ||
| $29.14M-4.5% | $30.53M-1.7% | $31.07M-3.8% | $32.3M-0.7% | $32.53M-1.4% | ||
| $65.49M-1.9% | $66.73M-2.4% | $68.38M-1.1% | $69.12M-2.6% | $70.93M-3.0% | ||
| $10.5M-5.2% | $11.07M+16.1% | $9.54M-8.3% | $10.4M+7.5% | $9.68M-4.2% | ||
| $260.68M-3.3% | $269.68M+1.5% | $265.64M-5.2% | $280.14M-1.8% | $285.42M-2.1% | ||
| $29.11M-17.8% | $35.39M+11.0% | $31.88M-4.2% | $33.29M+10.0% | $30.27M-12.9% | ||
| $4.66M-30.7% | $6.72M-23.1% | $8.74M+18.3% | $7.39M+28.3% | $5.76M-35.8% | ||
| $1.31M+0.1% | $1.31M-26.0% | $1.77M-3.6% | $1.84M+0.8% | $1.83M-2.8% | ||
| —— | —— | —— | $400K— | —— | ||
| $66.07M-8.2% | $71.96M+5.4% | $68.28M-10.4% | $76.2M-2.3% | $77.97M-12.0% | ||
| $2.41M-3.8% | $2.5M-3.5% | $2.59M-58.2% | $6.2M+123% | $2.78M— | ||
| $5.49M-5.1% | $5.79M+65.5% | $3.5M-11.4% | $3.95M-10.3% | $4.4M-10.4% | ||
| $2.41M-3.8% | $2.5M-3.5% | $2.59M-55.3% | $5.8M+109% | $2.78M— | ||
| $16.7M-2.1% | $17.05M+19.8% | $14.24M-15.8% | $16.9M-2.7% | $17.37M+46.6% | ||
| $87.32M-6.5% | $93.35M+7.6% | $86.79M-10.7% | $97.17M-2.4% | $99.55M-5.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $387K+0.3% | $386K0.0% | $386K+0.3% | $385K0.0% | $385K+0.3% | ||
| $632.18M+0.5% | $628.78M+0.5% | $625.89M+0.8% | $621.19M+0.3% | $619.55M+0.5% | ||
| -$454.53M-1.8% | -$446.45M-1.4% | -$440.1M-2.5% | -$429.2M-1.4% | -$423.15M-1.1% | ||
| $2.71M+171% | $998K+1,536% | $61K+103% | -$2.02M+42.7% | -$3.53M+5.8% | ||
| $7.38M0.0% | $7.38M0.0% | $7.38M0.0% | $7.38M0.0% | $7.38M0.0% | ||
| $173.36M-1.7% | $176.33M-1.4% | $178.86M-2.2% | $182.97M-1.6% | $185.87M-0.5% | ||
| $260.68M-3.3% | $269.68M+1.5% | $265.64M-5.2% | $280.14M-1.8% | $285.42M-2.1% | ||
| $10.5M-5.2% | $11.07M+16.1% | $9.54M-8.3% | $10.4M+7.5% | $9.68M-4.2% | ||
| $65.49M-1.9% | $66.73M-2.4% | $68.38M-1.1% | $69.12M-2.6% | $70.93M-3.0% | ||
| $10.5M-5.2% | $11.07M+16.1% | $9.54M-8.3% | $10.4M+7.5% | $9.68M-4.2% | ||
| $10.5M-5.2% | $11.07M+16.1% | $9.54M-8.3% | $10.4M+7.5% | $9.68M-4.2% | ||
| $32.3M+8.2% | $29.85M+7.9% | $27.66M-22.1% | $35.52M-3.9% | $36.95M-7.4% | ||
| $32.3M+8.2% | $29.85M+7.9% | $27.66M-22.1% | $35.52M-3.9% | $36.95M-7.4% | ||
| $4.66M-30.7% | $6.72M-23.1% | $8.74M+18.3% | $7.39M+28.3% | $5.76M-35.8% | ||
| $4.55M+5.1% | $4.33M+1.5% | $4.27M+4.8% | $4.07M-3.1% | $4.2M-3.0% | ||
| $7.9M-4.7% | $8.29M+36.1% | $6.09M-40.0% | $10.15M+41.5% | $7.17M+46.1% | ||
| —— | —— | —— | $4.07M— | —— | ||
| $632.18M+0.5% | $628.78M+0.5% | $625.89M+0.8% | $621.19M+0.3% | $619.55M+0.5% | ||
| $387K+0.3% | $386K0.0% | $386K+0.3% | $385K0.0% | $385K+0.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $4.55M+5.1% | $4.33M+1.5% | $4.27M+4.8% | $4.07M-3.1% | $4.2M-3.0% | ||
| —— | —— | —— | $4.07M— | —— | ||
| —— | —— | —— | $400K— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are AngioDynamics's total assets?
- AngioDynamics (ANGO) holds $260.7M in total assets, down 8.7% year over year.
- How much debt does AngioDynamics have?
- AngioDynamics carries $7.9M in total debt against $173.4M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does AngioDynamics have?
- AngioDynamics holds $37.8M in cash and equivalents.
- Can AngioDynamics cover its short-term obligations?
- Its current ratio is 2.35 — current assets exceed current liabilities.
- Where does AngioDynamics's balance sheet data come from?
- Every line is extracted from AngioDynamics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
